In vitro pharmacodynamics of CKD-602 in HT-29 cells

Archives of Pharmacal Research

Volumn 25, Issue 5, 2002, Pages 718-723

  Park, In Sook ^a   Mee, Ryung Ahn ^a   Soo, Kyung Suh ^a   Choi, Hong Serck ^a   Soo, Jung Sohn ^a   Ji, Sun Yang ^a   Tae, Moo Yoo ^b   Kuh, Hyo Jeong ^b  

^a Korea Food and Drug Administration   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

CKD 602; Delayed effect; Immediate effect; Intracellular uptake; Pharmacodynamics

Indexed keywords

7 (2 (N ISOPROPYLAMINO)ETHYL)CAMPTOTHECIN; 7-(2-(N-ISOPROPYLAMINO)ETHYL)CAMPTOTHECIN; CAMPTOTHECIN; DRUG DERIVATIVE;

ARTICLE; CELL STRAIN HT29; DRUG SCREENING; HUMAN; METHODOLOGY;

CAMPTOTHECIN; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS;

EID: 0036779425     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02976950     Document Type: Article

References (23)

1. Au, J.L-S., Li, D., Gan, Y., Gao, X., Johnson, A.L., Johston, J., Millenbaugh, N.J., Jang, S.H., Kuh, H., Chen, C. and Wientjes, M.G., Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention. Cancer Res., 58, 2141-2148 (1998).
2. Beijnen, J.H., Smiti, B.R., Keijer, W.J., Van Gijn, R., Ten Bokkel Huinink, W.W., Vlasveli, L. T., Rodenhuis, S. and Underberg, W. J. M., High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A(NSC 609699) in plasma. J. Pharm. & Biom. Anal., 8, 789-794 (1990).
3. Creemers, G.J., Lund. B. and Verweij, J., Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat. Rev., 20, 73-96 (1994).
4. Gerrits, C.J., Schellens, J.H., Burris, H., Eckardt, J.R., Planting, A.S., van Beurder Burg, A.M., Rodriguez, G.I. Loos, W.J. van Beurden V. and Verwei, J., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan. Clin. Cancer Res., 5, 69-75 (1999).
5. Gieschke R, and Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur. J. Drug Metab. Pharmacokinet., 25, 49-58 (2000).
6. Jew S.S, Kim M.G, Kim H.J, Rho E.Y, Park H.G, Kim J.K, Han H.J, and Lee H. Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring. Bioorg. Med. Chem. Lett., 8, 1797-1800 (1998).
7. Jung L.L, and Zamboni W.C. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist. Updat., 4, 273-288 (2001 ).
8. Kalns, J.E., Millenbaugh, N.J., Wientjes, M.G. and Au, J.L-S. Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res., 55, 5315-5322 (1995).
9. Kohn, K.W., and Pommier, Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann. N. Y. Acad. Sci., 922, 11-26 (2000).
10. Kuh, H. J., Jang, S.H., Wientjes, M.G., Weaver, J.R. and Au, J.L-S. Computational model of intracellular pharmacokinetics of paclitaxel. J. Pharmacol. & Exp. Ther., 293, 761-770 (2000).
11. Kuh, H. J., Jang, S.H., Wientjes, M.G., Weaver, J.R. and Au, J.L-S. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. & Exp. Ther., 871-880, 290 (1999).
12. Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y., Jew, S.S., Park, J.G., and Hong, C.I., Antitumor activity of 7-[2-(N-isopropylamino) ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590 (1998).
13. Lee, J.H., Lee, J.M., Lim, K.H., Kim, J.K., Ahn, S.K., Bang, Y.J., and Hong, C.I., Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann. N. Y. Acad. Sci., 922, 324-325 (2000).
14. Levasseur, L.M., Slocum, H.K., Rustum, Y.M., Greco, W.R., Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res., 58, 5749-5761 (1998).
15. Li, M.L, Horn, L, Firby, P.S., and Moore, M.J., Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Clin. Cancer Res., 7, 168-174 (2001).
16. Meibohm, B. and Derendorf, H. Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. & Ther., 35, 401-413 (1997).
17. Oguma, T., Ohshima, Y. and Nakaoka, M. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection, J. Chromatogr. B. Biomed. Sci. Appl., 740, 237-245 (2000).
18. Skipper, H.E., The effects of chemotherapy on the kinetics of leukemic cell. Cancer Res., 25, 1544-1550 (1965).
19. Slichenmyer, W.J., Rowinsky, E.K., Donehower, R.C., and Kaufmann, S.H., The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer. Inst., 85, 271-291 (1993).
20. Takimoto, C.H., Wright, J, and Arbuck, S.G., Clinical applications of the camptothecins. Biochim. Biophys. Acta, 1400, 107-119 (1998).
21. van den Bongard, H.J., Mathot, R.A., Beijnen, J.H., and Schellens, J.H., Pharmacokinetically guided administration of chemotherapeutic agents. Clin. Pharmacokinet., 39, 345-367 (2000).
22. Vigano, L., Locatelli, A., Grasselli, G., and Gianni, L., Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. Invest. New Drugs, 19, 179-196 (2001).
23. Wall, M.E., Wani, M.C., Cook, C.E., and Palmer, K.H. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3890 (1966).